Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects

J Clin Pharmacol. 2008 Feb;48(2):246-52. doi: 10.1177/0091270007312154.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Aged / physiology*
  • Area Under Curve
  • Benzylamines / blood
  • Benzylamines / metabolism
  • Biological Availability
  • Cholinesterase Inhibitors / administration & dosage
  • Cholinesterase Inhibitors / adverse effects
  • Cholinesterase Inhibitors / pharmacokinetics*
  • Chromatography, High Pressure Liquid
  • Cross-Over Studies
  • Dizziness / chemically induced
  • Female
  • Half-Life
  • Headache / chemically induced
  • Humans
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Nausea / chemically induced
  • Phenethylamines
  • Phenols / blood
  • Phenols / metabolism
  • Phenylcarbamates / blood
  • Phenylcarbamates / metabolism
  • Phenylcarbamates / pharmacokinetics*
  • Rivastigmine
  • Sleep Initiation and Maintenance Disorders / chemically induced
  • Solutions
  • Tandem Mass Spectrometry
  • Vomiting / chemically induced

Substances

  • 3-(1-dimethylaminoethyl)phenol
  • Benzylamines
  • Cholinesterase Inhibitors
  • Phenethylamines
  • Phenols
  • Phenylcarbamates
  • Solutions
  • Rivastigmine